Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Core Insights - Kyverna Therapeutics, Inc. is set to host a live webcast and conference call on December 15, 2025, to discuss topline results from the Phase 2 KYSA-8 clinical trial for KYV-101 in stiff person syndrome [1][2] Company Overview - Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, with its lead candidate KYV-101 advancing through late-stage clinical development [4] - KYV-101 is a fully human, autologous, CD19 CAR T-cell therapy designed for potency and tolerability, aiming for deep B-cell depletion and immune system reset [3][4] - The company is also conducting registrational trials for myasthenia gravis and has ongoing Phase 1/2 trials for lupus nephritis, with plans to explore additional indications such as multiple sclerosis and rheumatoid arthritis [4]